Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Pfizer

Status and phase: Completed; Phase 3

Conditions: Rheumatoid Arthritis

Treatments: Drug: CP-690,550

Study type: Interventional

Funder types: Industry

Identifiers

NCT00661661

A3921041

Details and patient eligibility

About

The purpose of this study is to determine the long-term effectiveness and safety of CP-690,550 for the treatment of rheumatoid arthritis. Subjects are only eligible for this study after they have completed participation in another "qualifying" study of CP-690,550.

Enrollment: 487 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects who have completed their participation in a randomized "qualifying" study of CP-690,550 for the treatment of rheumatoid arthritis

Exclusion criteria

• Serious medical conditions that would make treatment with CP-690,550 potentially unsafe

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

487 participants in 1 patient group

CP-690,550

Experimental group

Treatment:

Drug: CP-690,550